Recently, PRMT5 has become an attractive therapeutic target for the treatment of leukemia and lymphoma, with pre-clinical PRMT5-specific inhibitors displaying impressive in vivo efficacy in murine models of mantle cell lymphoma and chronic myelogenous leukemia (CML) (Chan-Penebre et al., 2015, Jin et al., 2016). Here, PRMT5 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.